Autolus Therapeutics (AUTL) vs Valneva (VALN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Autolus Therapeutics (AUTL) has outperformed Valneva (VALN) over the past year, gaining 0.6% versus a loss of 48.4%. Over five years, AUTL leads with a -71.2% price change compared with -79.7% for VALN. Valneva is the larger company by market cap ($544.3 million vs $471.1 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AUTL | VALN |
|---|---|---|
| Share price | $1.77 | $5.74 |
| Market cap | $471.11M | $544.29M |
| 1-day change | 0.00% | +0.88% |
| YTD return | -11.06% | -35.49% |
| 1-year return | +0.57% | -48.41% |
| 5-year return | -71.17% | -79.71% |
| Forward P/E | — | 4.82 |
| EPS (TTM) | $-1.06 | $-2.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.58 | $12.18 |
| 52-week low | $1.18 | $4.75 |
| Distance from 52-week high | -31.40% | -52.87% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +393.22% | +113.41% |
| Average volume | 2.10M | 78.17K |
| Shares outstanding | 266.16M | 94.82M |
| Employees | 752 | 620 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AUTL has outperformed VALN by 49.0 percentage points over the past year.
About Autolus Therapeutics
AUTL stock →Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases in the United Kingdom and internationally. The company offers AUCATZYL, a gene therapy product consisting of autologous T cells that are transduced with a lentiviral vector to express a novel anti-CD19 chimeric antigen receptor.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 752 employees
About Valneva
VALN stock →Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 620 employees
AUTL vs VALN FAQ
Which is bigger, Autolus Therapeutics or Valneva?
Valneva (VALN) is larger, with a market capitalization of $544.29M compared with $471.11M for Autolus Therapeutics (AUTL).
Which stock has performed better over the past year, AUTL or VALN?
AUTL returned +0.57% over the past 12 months, compared with -48.41% for VALN (price return, excluding dividends). Past performance does not predict future results.
Are Autolus Therapeutics and Valneva in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.